35. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434–438.
36. Vos MB, et al. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med. 2008; 10: 160.
37. Maruhama Y, Macdonald I. Incorporation of orally administered glucose-U-14C and fructose-U-14C into the triglyceride of liver, plasma, and adipose tissue of rats. Metabolism. 1973; 22(9): 1205–1215.
38. Geidl-Flueck B, et al. Fructose and sucrose but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. J. Hepatol. 2021; 75: 46–54.
39. Stanhope KL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Investig. 2009; 119: 1322–1334.
40. Lanaspa MA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and independent fatty liver. J Biol Chem. 2012; 287(48): 40732–40744.
41. Ouyang X, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6): 993–999.
42. Maersk M, et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012; 95(2): 283–289.
43. Schwarz JM, et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017; 153(3): 743–752.
44. Jensen T. et al. Fructose and Sugar: A Major Mediator of Nonalcoholic Fatty Liver Disease. J Hepatol. J Hepatol. 2018; 68(5): 1063–1075.
45. Wenting Wang, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study. Scientific Reports. 2022; 12: 10 977.
46. Wei H, et al. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study. BMJ Open. 2016; 6.
47. Ruohui Xu a, et al. Recent advances in lean NAFLD. Biomedicine & Pharmacotherapy. 153 (2022) 113331: 1–8.
48. Eslam, M. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73: 202–209.
49. Hart CL, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010; 340.